Takeru Kusumoto

Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial

H. Hoshiai, Yoshifumi Seki, Takeru Kusumoto, 2021, BMC Women's Health.

Formation of lipid droplets induced by 2,3-dihydrogeranylgeranoic acid distinct from geranylgeranoic acid.

Y. Matsumura, Takeshi Takahashi, Y. Shidoji, 2007, Acta biochimica Polonica.

Experimental quantum kernel trick with nuclear spins in a solid

Keisuke Fujii, Makoto Negoro, Masahiro Kitagawa, 2019, npj Quantum Information.

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.

N. Terakawa, Y. Osuga, Yoshifumi Seki, 2020, Fertility and sterility.

Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results

N. Terakawa, Y. Osuga, Yoshifumi Seki, 2021, BMC Women's Health.

Experimental quantum kernel trick with nuclear spins in a solid

K. Mitarai, M. Kitagawa, M. Negoro, 2021, npj Quantum Information.